Even though many potent and specific inhibitors have been developed against virtually all oncogenic kinases [18], only one small molecule kinase inhibitor for VEGFR, regorafenib (BAY 73-4506), has been approved for CRC targeted therapy [19]. Here, KDR is linked to colorectal carcinoma.